|
62 Companies |
|
71 Products |
|
71 Products |
|
81 Mechanisms of Action |
|
10 Trials |
|
587 News |
|
| «12345678910111213» |
- Clinical: DIETSAN: Different Bowel Preparations in CT Colonography: is Diet Necessary? A Randomized Controlled Trial (clinicaltrials.gov) - Feb 26, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: University of Roma La Sapienza
- Erbitux (cetuximab) / Eli Lilly, Perjeta (pertuzumab) / Roche
Enrollment change, Trial termination: Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 23, 2015
P1/2, N=17, Terminated, Sponsor: National Cancer Institute (NCI)
N=50 --> 17 | Active, not recruiting --> Terminated
- Trial completion, Trial primary completion date: Right-sided Colon Tumor, Laparoscopic Versus Open Surgery, in an ERAS Protocol (clinicaltrials.gov) - Feb 20, 2015
P=N/A, N=125, Completed, Sponsor: Karolinska Institutet
N=50 --> 17 | Active, not recruiting --> Terminated Active, not recruiting --> Completed | Trial primary completion date: Dec 2012 --> Jul 2014
- Trial initiation date, Trial primary completion date: Sentinel Node Mapping With Indocyanine Green in Colon Cancer: a Feasibility Trial and a Descriptive Serie. (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=30, Not yet recruiting, Sponsor: Ismail G
Active, not recruiting --> Completed | Trial primary completion date: Dec 2012 --> Jul 2014 Initiation date: Jun 2014 --> Feb 2015 | Trial primary completion date: May 2015 --> Feb 2016
- Enrollment open: Endocuff-assisted vs. Standard Colonoscopy (clinicaltrials.gov) - Feb 15, 2015
P=N/A, N=200, Recruiting, Sponsor: Attikon Hospital
Initiation date: Jun 2014 --> Feb 2015 | Trial primary completion date: May 2015 --> Feb 2016 Not yet recruiting --> Recruiting
- || Trial primary completion date: Study of Economic Circumstances, Service Utilization, and Service Needs Among Older Colon Cancer Patients (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=62, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2014 --> Oct 2015
- Trial suspension, Trial primary completion date, Surgery, Metastases: Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases (clinicaltrials.gov) - Feb 2, 2015
P1, N=40, Suspended, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Oct 2014 --> Oct 2015 Recruiting --> Suspended | Trial primary completion date: Apr 2014 --> Apr 2015
- || Enrollment change: A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=30000, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Suspended | Trial primary completion date: Apr 2014 --> Apr 2015 N=25000 --> 30000
- veliparib (ABT-888) / AbbVie
Enrollment closed, Combination therapy: A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) - Jan 22, 2015
P1, N=48, Active, not recruiting, Sponsor: AbbVie
N=25000 --> 30000 Enrolling by invitation --> Active, not recruiting
- morphine sulphate / Generic mfg.
Enrollment open, Surgery, Minimal residual disease: Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery (clinicaltrials.gov) - Jan 20, 2015
P4, N=60, Recruiting, Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- Trial primary completion date: Full Spectrum vs. Standard Forward-viewing Colonoscopy (clinicaltrials.gov) - Jan 17, 2015
P=N/A, N=200, Recruiting, Sponsor: Attikon Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Apr 2015
- Clinical: Endocuff-assisted vs. Standard Colonoscopy (clinicaltrials.gov) - Jan 17, 2015
P=N/A, N=200, Not yet recruiting, Sponsor: Attikon Hospital
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 15, 2015
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Apr 2015 Trial primary completion date: Dec 2014 --> Mar 2015
- || Avastin (bevacizumab) / Roche
Trial initiation date: Follow up to the AVANT Study up to 8 and 10 Years (Median Follow up) in Patients With Colon Carcinoma (clinicaltrials.gov) - Jan 12, 2015
P=N/A, N=3451, Not yet recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Trial primary completion date: Dec 2014 --> Mar 2015 Initiation date: Oct 2014 --> Jan 2015
- Avastin (bevacizumab) / Roche
Enrollment change, Trial termination, Trial primary completion date, Surgery, Metastases: Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 9, 2015
P2, N=1, Terminated, Sponsor: City of Hope Medical Center
Initiation date: Oct 2014 --> Jan 2015 N=25 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Dec 2014; Slow accrual.
- Enrollment closed, Enrollment change, Trial primary completion date: Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer (clinicaltrials.gov) - Jan 8, 2015
P1, N=10, Active, not recruiting, Sponsor: Thomas Jefferson University
N=25 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Dec 2014; Slow accrual. Recruiting --> Active, not recruiting | N=44 --> 10 | Trial primary completion date: Oct 2018 --> Jun 2014
- luminespib (AUY922) / Ligand, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Metastases: Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 8, 2015
P1, N=18, Active, not recruiting, Sponsor: Swedish Medical Center
Recruiting --> Active, not recruiting | N=44 --> 10 | Trial primary completion date: Oct 2018 --> Jun 2014 Recruiting --> Active, not recruiting
- erlotinib / Generic mfg.
Trial completion: Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma (clinicaltrials.gov) - Jan 6, 2015
P2a, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Trial primary completion date: A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics (clinicaltrials.gov) - Dec 25, 2014
P=N/A, N=25000, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Dec 2015
- Recentin (cediranib) / AstraZeneca, RG4733 / Roche
Trial completion, Enrollment change, Metastases: Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 24, 2014
P1, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Completed | N=50 --> 20
- Biomarker, Trial primary completion date, IO biomarker: PPS4B: Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention (clinicaltrials.gov) - Dec 13, 2014
P3, N=800, Active, not recruiting, Sponsor: Emory University
Active, not recruiting --> Completed | N=50 --> 20 Trial primary completion date: Nov 2013 --> Dec 2014
- Enrollment open, Trial initiation date: Programs to Support You During Chemotherapy (Pro-You) (clinicaltrials.gov) - Dec 13, 2014
P=N/A, N=40, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Trial primary completion date: Nov 2013 --> Dec 2014 Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014
- | veliparib (ABT-888) / AbbVie
Trial completion: A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors (clinicaltrials.gov) - Dec 13, 2014
P1, N=45, Completed, Sponsor: AbbVie
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014 Active, not recruiting --> Completed
- Trial primary completion date: Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer (clinicaltrials.gov) - Dec 12, 2014
P1, N=44, Recruiting, Sponsor: Thomas Jefferson University
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Oct 2018
- Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Surgery, Metastases: COMBATAC: Combined Anticancer Treatment of Advanced Colon Cancer (clinicaltrials.gov) - Dec 12, 2014
P2, N=60, Active, not recruiting, Sponsor: University of Regensburg
Trial primary completion date: Jun 2014 --> Oct 2018 Recruiting --> Active, not recruiting
- | morphine sulphate / Generic mfg.
New P4 trial, Surgery, Minimal residual disease: Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery (clinicaltrials.gov) - Dec 11, 2014
P4, N=60, Not yet recruiting, Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic
- Trial completion: Impact of a Novel Patient Educational Booklet on Colonoscopy Quality (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=500, Completed, Sponsor: VA Greater Los Angeles Healthcare System
Recruiting --> Active, not recruiting Recruiting --> Completed
- || Trial primary completion date: SSN: Initiation of Colon Cancer Screening in Veterans or "Start Screening Now" (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=1504, Active, not recruiting, Sponsor: The University of Texas Health Science Center, Houston
Recruiting --> Completed Trial primary completion date: Feb 2014 --> Jul 2015
- New P1 trial: EACC: Endoscopically Assisted Colostomy With Colopexy for Critically Ill Patients Without General Anesthesia or Laparotomy (clinicaltrials.gov) - Dec 6, 2014
P1, N=5, Completed, Sponsor: University of Sao Paulo
- | Avastin (bevacizumab) / Roche
Trial completion: TOSCA: FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer (clinicaltrials.gov) - Nov 28, 2014
P3, N=3756, Completed, Sponsor: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Trial primary completion date: Feb 2014 --> Jul 2015 Recruiting --> Completed
- ||| Surgery: Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing (clinicaltrials.gov) - Nov 25, 2014
P=N/A, N=150, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Enrollment change, Trial termination, Surgery: Implementation of Laparoscopy-assisted Surgery for Colon Cancer (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=60, Terminated, Sponsor: Helse Stavanger HF
Recruiting --> Completed N=270 --> 60 | Recruiting --> Terminated; Study had to be terminated due to lack of funding
- Enrollment open, Enrollment change, Trial primary completion date: Full Spectrum vs. Standard Forward-viewing Colonoscopy (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=200, Recruiting, Sponsor: Attikon Hospital
N=270 --> 60 | Recruiting --> Terminated; Study had to be terminated due to lack of funding Not yet recruiting --> Recruiting | N=120 --> 200 | Trial primary completion date: Apr 2014 --> Dec 2014
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 13, 2014
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | N=120 --> 200 | Trial primary completion date: Apr 2014 --> Dec 2014 Trial primary completion date: Aug 2014 --> Nov 2014
- Clinical: Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=2910, Recruiting, Sponsor: University of Michigan
- veliparib (ABT-888) / AbbVie
Enrollment closed: A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors (clinicaltrials.gov) - Nov 13, 2014
P1, N=48, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: Aug 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- Trial initiation date: Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=72, Not yet recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting Initiation date: May 2014 --> May 2015
- RG4733 / Roche
Trial completion: RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) - Nov 7, 2014
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: May 2014 --> May 2015 Active, not recruiting --> Completed
- ||| Enrollment closed: Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer (clinicaltrials.gov) - Oct 28, 2014
P2, N=120, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- CYT107 / Revimmune
Trial primary completion date: Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy (clinicaltrials.gov) - Oct 24, 2014
P2, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2015 --> Apr 2017
- Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
Enrollment open: EMPIRE: Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function (clinicaltrials.gov) - Oct 10, 2014
P4, N=44, Recruiting, Sponsor: Medical Center Alkmaar
Trial primary completion date: Apr 2015 --> Apr 2017 Not yet recruiting --> Recruiting
- Enrollment closed, Trial primary completion date: VATNIMAD: Validation of an Alternative Biological Test to Increase the Detection Sensitivity of a Colon Tumour (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=502, Active, not recruiting, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Dec 2014
- Trial primary completion date: Screening for Gynecologic Cancers in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Patients (clinicaltrials.gov) - Sep 30, 2014
P=N/A, N=95, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Dec 2014 Trial primary completion date: May 2015 --> May 2016
- Avastin (bevacizumab) / Roche, GI-4000 / ImmunityBio
Enrollment change, Trial termination, Metastases: A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI (clinicaltrials.gov) - Sep 28, 2014
P2, N=11, Terminated, Sponsor: Georgetown University
Trial primary completion date: May 2015 --> May 2016 N=52 --> 11 | Active, not recruiting --> Terminated; Poor accrual rate
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=52 --> 11 | Active, not recruiting --> Terminated; Poor accrual rate Phase classification: P1/2 --> P1
- luminespib (AUY922) / Ligand, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2014
P1, N=18, Recruiting, Sponsor: Swedish Medical Center
Phase classification: P1/2 --> P1 Trial primary completion date: Feb 2014 --> Nov 2014
- Enrollment change, Trial initiation date: The Impact of Warmed Carbon Dioxide Insufflation During Colonoscopy on Polyp Detection (clinicaltrials.gov) - Sep 19, 2014
P4, N=444, Recruiting, Sponsor: Queen's University
Trial primary completion date: Feb 2014 --> Nov 2014 N=110 --> 444 | Initiation date: Feb 2014 --> Jun 2014
- Clinical: GI SPORE Colon Biosample Protocol (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=1500, Recruiting, Sponsor: University of Michigan
- Trial primary completion date, Surgery: Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery (clinicaltrials.gov) - Sep 15, 2014
P1, N=20, Completed, Sponsor: National Cancer Institute (NCI)
N=110 --> 444 | Initiation date: Feb 2014 --> Jun 2014 Trial primary completion date: Mar 2009 --> Nov 2008
- Farydak (panobinostat) / Secura Bio
Enrollment change, Trial termination, Metastases: Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy (clinicaltrials.gov) - Sep 11, 2014
P1, N=7, Terminated, Sponsor: University of Southern California
Trial primary completion date: Mar 2009 --> Nov 2008 N=50 --> 7 | Suspended --> Terminated; Adverse Events